SCHEMBL234056

SCHEMBL234056

CCN(CC)C(=O)Nc1ccccc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.59
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
PKM P14618 1/20 0.59
CDK5 Q00535 1/20 0.59
CDK5R1 Q15078 1/20 0.59
ABCC1 P33527 2/20 0.54
NPSR1 Q6W5P4 1/20 0.53
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
LMNA P02545 1/20 0.50
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ALPL P05186 1/20 0.48
ALPI P09923 1/20 0.48
ALPG P10696 1/20 0.48
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13930304 0.85 NPSR1 (0.55) SMN1; SMN2RAB9ANPC1PKMCDK5
SCHEMBL234520 0.81 RAB9A (0.58) SMN1; SMN2RAB9ANPC1ABCC1LMNA
SCHEMBL7256367 0.81 ABCC1 (0.55) RAB9ANPC1PKMABCC1LMNA
SCHEMBL23169175 0.80 HTT (0.64) SMN1; SMN2RAB9ANPC1NPSR1LMNA
SCHEMBL10434939 0.80 ABCC1 (0.54) SMN1; SMN2RAB9ANPC1ABCC1LMNA
SCHEMBL16599594 0.79 ABCC1 (0.54) RAB9ANPC1ABCC1TAS1R3TAS1R1
SCHEMBL8342447 0.79 ABCC1 (0.53) SMN1; SMN2RAB9ANPC1ABCC1LMNA
SCHEMBL13951853 0.77 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1PKMCDK5
SCHEMBL17430271 0.77 RAB9A (0.58) SMN1; SMN2RAB9ANPC1NPSR1LMNA
SCHEMBL1063418 0.77 NPSR1 (0.71) SMN1; SMN2RAB9ANPC1PKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362067-B2 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
EP-2265582-B1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. SANOFI SA (FR) 2012-01-04 EP disclosed
CN-102015642-A Novel 3-aminoalkyl-1, 3-dihydro-2H-indol-2-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS 2011-04-13 CN disclosed
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
EP-2265582-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. Sanofi-Aventis (FR) 2010-12-29 EP disclosed
WO-2009115685-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. SANOFI-AVENTIS (FR) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF AVPR1B, AVPR1A, AVPR2 SMN1; SMN2 4837/4885RAB9A 947/4885NPC1 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.